Log In Sign up
The largest database of trusted experimental protocols

Sk006

Manufactured by Agilent Technologies
Visit Supplier
Sourced in Denmark

The SK006 is a laboratory centrifuge device designed for general laboratory use. It is capable of separating materials of different densities by applying centrifugal force. The device's core function is to provide a controlled environment for the separation of samples.

Automatically generated - may contain errors

Lab products found in correlation

Benchmark ultra, by Roche (2 mentions) Sk005, by Agilent Technologies (2 mentions) Dako autostainer link 48 instrument, by Agilent Technologies (2 mentions) Sp142, by Roche (2 mentions) Sp263, by Roche (2 mentions) E1l3n, by Cell Signaling Technology (2 mentions) Ab205921, by Abcam (1 mentions)

3 protocols using sk006

1

Peptide Array Screening of PD-L1 Epitopes

Check if the same lab product or an alternative is used in the 5 most similar protocols
An extensive library of linear peptides for continuous epitopes and nonlinear, discontinuous, conformationally constrained, peptide mimics corresponding to the PD-L1 extracellular domain (residues 19–239) and the cytoplasmic domain (residues 260–290) was designed and used to create a peptide array by the Chemical Linkage of Peptides on Scaffolds (CLIPS; Pepscan Presto, Netherlands) technique [35 (link), 36 (link)]. All peptides were synthesized on solid support and screened with varying concentrations of antibody and blocking buffer to optimize signal-to-noise ratios in each experiment. Arrays were probed with SP263 (790-4905; Ventana Medical Systems, Inc., USA), SP142 (M4422; Spring BioScience, USA), 22C3 RTU (SK006; Dako, Denmark), 28-8 (ab205921; Abcam, UK), and recombinant 22C3 and 28-8 antibodies described in the following section. The binding of antibodies to each peptide construct of the entire library was determined.
Lawson N.L., Dix C.I., Scorer P.W., Stubbs C.J., Wong E., Hutchinson L., McCall E.J., Schimpl M., DeVries E., Walker J., Williams G.H., Hunt J, & Barker C. (2019). Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Modern Pathology, 33(4), 518-530.
+ Open protocol
+ Expand
2

Multisite Evaluation of PD-L1 Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
PD-L1 expression was evaluated by quantitative immunofluorescence (QIF) and chromogenic IHC using five monoclonal antibodies (Suppl. Table 1), including both LDT and FDA-approved assays. For QIF, clones E1L3N (#13684, Cell Signaling Technology, Inc.), SP142 (#M4420, SpringBio), and SP263 (#790–4905, Ventana Medical Systems, Inc.) were assessed. For chromogenic IHC, automated systems were used for different clones using our own protocol for the LDT E1L3N (#13684, Cell Signaling Technology, Inc.) on multiple platforms, and protocols specified by corresponding manufacturer per the FDA labeling for 22C3 (#SK006, Dako) and 28–8 (#SK005, Dako) with the Dako Autostainer Link 48 Instrument (Dako). Similarly, on label protocols were used for FDA-approved assays; SP263 (#740–4907) and SP142 (#740–4859) both from Ventana Medical Systems, Inc. on the Benchmark Ultra (Ventana Medical Systems, Inc.). For the multi-institutional comparison, twelve 5-µm sections per PD-L1 assay were cut from a block of Index TMA at Yale University and sent to 12 institutions for staining weekly during 6 consecutive weeks, running 2 slides per week with their clinical workload using the assay of choice for each institution.
Martinez-Morilla S., McGuire J., Gaule P., Moore L., Acs B., Cougot D., Gown A.M., Yaziji H., Wang W.L., Cartun R.W., Hornick J.L., Sholl L.M., Qiu J., Mino-Kenudson M., Yi E.S., Beasley M.B., Merrick D.T., Ambaye A.B., Zhang Z.J., Walker J, & Rimm D.L. (2019). Quantitative Assessment of PD-L1 as an Analyte in Immunohistochemistry Diagnostic Assays using a Standardized Cell Line Tissue Microarray. Laboratory investigation; a journal of technical methods and pathology, 100(1), 4-15.
+ Open protocol
+ Expand
3

Multisite Evaluation of PD-L1 Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
PD-L1 expression was evaluated by quantitative immunofluorescence (QIF) and chromogenic IHC using five monoclonal antibodies (Suppl. Table 1), including both LDT and FDA-approved assays. For QIF, clones E1L3N (#13684, Cell Signaling Technology, Inc.), SP142 (#M4420, SpringBio), and SP263 (#790–4905, Ventana Medical Systems, Inc.) were assessed. For chromogenic IHC, automated systems were used for different clones using our own protocol for the LDT E1L3N (#13684, Cell Signaling Technology, Inc.) on multiple platforms, and protocols specified by corresponding manufacturer per the FDA labeling for 22C3 (#SK006, Dako) and 28–8 (#SK005, Dako) with the Dako Autostainer Link 48 Instrument (Dako). Similarly, on label protocols were used for FDA-approved assays; SP263 (#740–4907) and SP142 (#740–4859) both from Ventana Medical Systems, Inc. on the Benchmark Ultra (Ventana Medical Systems, Inc.). For the multi-institutional comparison, twelve 5-µm sections per PD-L1 assay were cut from a block of Index TMA at Yale University and sent to 12 institutions for staining weekly during 6 consecutive weeks, running 2 slides per week with their clinical workload using the assay of choice for each institution.
Martinez-Morilla S., McGuire J., Gaule P., Moore L., Acs B., Cougot D., Gown A.M., Yaziji H., Wang W.L., Cartun R.W., Hornick J.L., Sholl L.M., Qiu J., Mino-Kenudson M., Yi E.S., Beasley M.B., Merrick D.T., Ambaye A.B., Zhang Z.J., Walker J, & Rimm D.L. (2019). Quantitative Assessment of PD-L1 as an Analyte in Immunohistochemistry Diagnostic Assays using a Standardized Cell Line Tissue Microarray. Laboratory investigation; a journal of technical methods and pathology, 100(1), 4-15.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!